Royal Bank of Canada boosts stakes in Sanofi and Novo Nordisk
Royal Bank of Canada increased its equity holdings in two major pharmaceutical companies during the first quarter. The bank bought an additional 470,882 shares of Sanofi, bringing its total to 3,155,080 shares, which represents about 0.13 % of Sanofi’s outstanding stock and is valued at roughly $152 million.
In a separate filing, RBC added 141,376 shares of Novo Nordisk, raising its total position to 4,527,779 shares, or about 0.10 % of the Danish drugmaker, worth approximately $166.4 million. Both filings were disclosed in the bank’s recent SEC 13‑F report.
Entities: Mark A. Goldsmith · Novo Nordisk A/S · Readystate Asset Management LP · Revolution Medicines Inc. · Royal Bank of Canada · Sanofi · Stephen Michael Kelsey · daraxonrasib
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] The Sanofi holding represented 0.13% of the company and was valued at $152,011,000. (SEC filing)
- [○ 1 SOURCE] Royal Bank of Canada increased its Novo Nordisk stake by 3.2% in Q1, ending with 4,527,779 shares. (SEC filing)
- [○ 1 SOURCE] Royal Bank of Canada increased its Sanofi stake by 17.5% in Q1, ending with 3,155,080 shares. (SEC filing)
- [○ 1 SOURCE] The Novo Nordisk holding represented about 0.10% of the company and was valued at $166,396,000. (SEC filing)